|
VOLta Medical AI-software in REal-World During AF Ablation
RECRUITINGSponsored by Volta Medical
Actively Recruiting
SponsorVolta Medical
Started2026-06-16
Est. completion2030-06
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT07621055
Summary
This PMCF study "VOLTAIRE-AF" will allow to observe acute and long-term safety and performance outcomes of the last generation of Volta Medical AI software (Volta AF-Xplorer II) during AF ablation using next-generation mapping and ablation technologies over a 24-month follow-up and in "real life"clinical practice, without any imposed clinical workflow.
Eligibility
Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria: 1. Patient aged 18 years or older. 2. Patient candidate for catheter ablation to treat paroxysmal or persistent atrial fibrillation, atrial tachycardia, de novo or after one or several previous ablation procedures, and for which the investigator considers using Volta AF-Xplorer II. 3. Patient able and willing to provide written informed consent to participate in the study. 4. Only for France: Patient affiliated to the French social security system. Exclusion Criteria: 1. Contraindication to AF/AT catheter ablation using RF and/or PFA. 2. Patient who is or could potentially be pregnant. 3. Person deprived of liberty or under guardianship. 4. Person unable to undergo a medical monitoring for geographical, social or psychological reasons. 5. Patient's refusal to participate in the study. 6. Enrollment in a premarket clinical study evaluating device, drug or biologic product.
Conditions4
Arrhythmias, CardiacAtrial ArrhythmiaAtrial FibrillationHeart Disease
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
SponsorVolta Medical
Started2026-06-16
Est. completion2030-06
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT07621055